• All sections
  • C - Chemistrymetallurgy
  • C07D - Heterocyclic compounds
  • C07D 211/32 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Patent holdings for IPC class C07D 211/32

Total number of patents in this class: 256

10-year publication summary

15
22
20
16
15
10
20
9
5
3
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026

Principal owners for this class

Owner
All patents
This class
Theravance Biopharma R&D IP, LLC
408
17
Incyte Holdings Corporation
626
9
Incyte Corporation
1068
8
Merck Sharp & Dohme LLC
3728
6
Glaxosmithkline LLC
528
5
Janssen Pharmaceutica N.V.
3177
5
Arvinas Operations, Inc.
262
5
F. Hoffmann-La Roche AG
7832
4
Boehringer Ingelheim International GmbH
4501
4
Merck Patent GmbH
5725
4
National University Corporation Hokkaido University
1362
4
The Regents of the University of California
20690
3
Nerviano Medical Sciences S.r.l.
236
3
The United States Government AS represented by The Department of Veterans Affairs
1328
3
Zhejiang Huahai Pharmaceutical Co., Ltd.
218
3
Universite de Caen Normandie
127
3
Eccogene Inc.
11
3
Bristol-myers Squibb Company
4721
2
Genentech, Inc.
4101
2
Syngenta Limited
429
2
Other owners 161